Ultime notizie per AN2 Therapeutics (NASDAQ:ANTX) Azioni

AN2 THERAPEUTICS INC

Anthem

AN2 Therapeutics

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

AN2 Therapeutics Inc

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Instacart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>)</h3>
<ul>
<li>On April 3, Wells Fargo analyst Ken Gawrelski maintained Maplebear with an Equal-Weight rating and lowered the price target from $47 to $44. The company's stock fell around 6% over the past month and has a 52-week low of $29.84.</li>
<li>RSI Value:30</li>
<li>CART Price Action: Shares of Instacart fell 6.6% to close at $37.37 on Friday.</li>
<li>Edge Stock Ratings: 73.72 Momentum score with Value at 57.23. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/cart"><img loading="lazy" decoding="async" width="440" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071358/image-57.png" alt="" class="wp-image-859673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071358/image-57.png 440w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071358/image-57-300x115.png 300w" sizes="(max-width: 440px) 100vw, 440px" /></a></figure>
<h3 class="wp-block-heading">Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On March 20, Stifel analyst Mark Astrachan maintained Walmart with a Hold and lowered the price target from $99 to $93. The company's stock fell around 9% over the past month and <a href="https://www.benzinga.com/quote/WMT">has a 52-week low</a> of $58.56.</li>
<li>RSI Value: 29.5</li>
<li>WMT Price Action: Shares of Walmart dipped 4.7% to close at $83.19 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407">trend in WMT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407"><img loading="lazy" decoding="async" width="917" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58.png" alt="" class="wp-image-859674" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071504/image-58-768x701.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Archer-Daniels-Midland Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>)</h3>
<ul>
<li>On March 27, ADM And Mitsubishi signed a memorandum of understanding to explore potential areas of collaboration across agriculture supply chain. The company's stock fell around 12% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/ADM"> low of $43.01</a>.</li>
<li>RSI Value: 22.4</li>
<li>ADM Price Action: Shares of Archer-Daniels-Midland fell 8.9% to close at $43.32 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407">ADM shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0407"><img loading="lazy" decoding="async" width="798" height="737" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59.png" alt="" class="wp-image-859676" style="width:462px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59.png 798w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07071553/image-59-768x709.png 768w" sizes="(max-width: 798px) 100vw, 798px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo via Shutterstock

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CART

Top 3 Defensive Stocks That Are Preparing To Pump This Month

CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small cell lung cancer (sqNSCLC). CVHNLC is CureVac's investigational mRNA-based precision immunotherapy consisting of two different mRNA constructs encoding eight tumor-associated antigens (TAAs) with prevalence across sqNSCLC patients. Encoded antigens include a novel class of TAAs that have not been previously tested in cancer immunotherapy trials.
The phase 1, dose-finding, open-label study will assess the safety and tolerability of CVHNLC plus pembrolizumab in patients with advanced sqNSCLC. The study comprises a dose-escalation part (Part A) of first-line maintenance treatment after either chemotherapy combined with pembrolizumab or pembrolizumab monotherapy. This is followed by an optional dose expansion part (Part B) in which CVHNLC is tested in combination with first-line chemotherapy and pembrolizumab.

Government

Regulations

CVAC

MRNA

CureVac Gets FDA Green Light for Lung Cancer Trial With mRNA-Based Immunotherapy

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower on continued weakness following President Trump's recent tariff announcements, which have caused global trade war concerns.

Wallbox Celebrates 100K EV Chargers Made In Arlington; Commits To Long-Term U.S. Electrification Push

enCore Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EU#NASDAQ">EU</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/EU#TSXV">EU</a>) (the "Company" or "enCore"), announced today the results of the most successful month at the Alta Mesa In-Situ Recovery Uranium Central Processing Plant ("CPP") since commencing operations in June 2024. Following previously announced improvements to operations (see <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4399711-1&amp;h=2814273370&amp;u=https%3A%2F%2Fencoreuranium.com%2Fnews%2Fencore-energy-expands-uranium-extraction-capacity-at-alta-mesa-accelerated-wellfield-development-underway%2F&amp;a=EU+NR+dated+March+13%2C+2025">EU NR dated March 13, 2025</a>) with the goal of expanding uranium extraction, decreasing unnecessary costs and increasing efficiency, the Company captured 50,000 pounds of uranium ("U3O8") in the last 26 days in March 2025.&nbsp; With a healthy treasury including unencumbered cash, inventory and marketable securities of ~$40 million USD, the Company continues to improve Alta Mesa CPP operations and the wellfield development program, which is now on track to meet 2025 contract projections. The Company also announced the appointment of Rob Willette, Acting Chief Executive Officer ("A/CEO"), to the Board of Directors and the promotion of Daniel Calderon to Director of Texas Operations. &nbsp;Mr. Willette will hold the Board seat dedicated to the Chief Executive Officer until such time a permanent appointment is made.
 &nbsp;

TSXV:EU

enCore Energy Boosts Production, Appoints Acting CEO Rob Willette to Board Amid Strong Cash Reserves, Hits Uranium Output Milestone With 50,000 Pounds Captured in March

cbdMD initiated this process in March 2021, with the submission of a comprehensive dossier detailing the ingredient's identity, quality, stability, hemp sourcing, extraction controls, labeling, testing requirements, usage instructions, and extensive safety data. In February 2022, cbdMD became the first U.S. brand to receive dossier validation. Since then, cbdMD has worked closely with the FSA, actively addressing inquiries to expedite the regulatory review process.

Health Care

General

YCBD

Cbdmd Announces That Food Dossier Has Advanced To The Last Phase Of Regulatory Assessment With The UK Food Standards Agency, Nearing Final Approval

EON Resources Inc. (NYSE:<a href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) ("EON" or the "Company") is an independent upstream energy company with oil and gas properties in the Permian Basin. Given the current volatility in the market, the Company's contractual hedging program mitigates the negative impact of reduced oil price risk through the end of CY 2025.
Approximately 70% of the Company's oil production is contractually hedged.
Hedge prices the Company receives are from $70.10 to $70.50 per barrel.
The hedges are established and fixed in volume and price for the next 9 months.
"EON has a very responsible hedging program designed to protect the Company from volatile swings in oil prices as we have witnessed this week apparently driven by the expected increase in oil production by Saudi Arabia," said Mitchell B. Trotter, CFO of EON. "While we do not believe that the current oil price volatility will last for an extended period of time, our hedging program mitigates a negative impact to our financial results."

EONR

EON Resources Locks In Oil Prices at $70+ Through 2025 to Guard Against Market Volatility

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $15 to $16.

ANGO

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $16

<a href="https://www.globenewswire.com/Tracker?data=Yw-TWCZN9-grHtHI6xQ1MISsc5A_cnAd6iOP9HS2de_E9bO6kmRPpQ7-DdhCIp1XU_MLP8EPDO09LPQydV9zw0TvgUE4ojq7agmELTp5-SL1MHzrzstoyetmyPIknCr7">Plymouth Industrial REIT, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the first quarter of 2025. The Company also announced details for its first quarter earnings conference call and webcast to be held on May 2, 2025.
Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, "Our strong leasing activity in the first quarter underscores the continued demand for well-located, functional industrial space across our markets. Additionally, our acquisition activity remains disciplined and strategic, as we continue to expand our footprint in key logistics hubs with assets that we expect will offer immediate cash flow and long-term value creation."
Leasing Activity Leases commencing during the first quarter ended March 31, 2025, all of which have terms of at least six months, totaled an aggregate of 2,437,267 square feet. These leases included 1,540,756 square feet of renewal leases and 896,511 square feet of new leases. Excluding the effect of the previously announced executed two-year lease at our 769,500-square-foot Class A building in St. Louis (the "St. Louis lease") that commenced on January 15, 2025, rental rates under these leases reflect a 16.2% increase on a cash basis with renewal leases reflecting a 15.0% increase on a cash basis and new leases reflecting a 22.1% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 9.6% on a cash basis and new leases would have increased 0.9% on a cash basis.
Same store occupancy at March 31, 2025, was 94.7%.&nbsp;&nbsp; Total portfolio occupancy at March 31, 2025, was 94.3% which reflects changes from last quarter including a 210-basis-point positive impact from the St. Louis lease, a 45-basis-point positive impact from leasing in in Cleveland, a 15-basis-point positive impact from acquisitions in Cincinnati and Atlanta markets and a net 70-basis-point negative impact from other leasing activity in the quarter.
Executed leases that will commence during 2025, all of which have terms of at least six months, totaled an aggregate of 4,652,684 square feet. These leases, which represent 56.3% of total 2025 expirations, include 3,731,230 square feet of renewal leases (30.0% of these renewal leases were associated with contractual renewals; there only remains a potential of 120,641 square feet of contractual renewals left in 2025) and 921,454 square feet of new leases, of which 740,487 square feet was vacant at the start of 2025. Excluding the effect of the St. Louis lease, rental rates under these leases reflect a 21.8% increase on a cash basis with renewal leases reflecting a 14.7% increase in rental rates on a cash basis and new leases reflecting a 15.3% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 12.1% on a cash basis and new leases would have increased 1.7% on a cash basis.
Acquisition Activity During the first quarter of 2025, Plymouth closed on the acquisition of six industrial buildings totaling 801,161 square feet for a total of $65.1 million and a weighted average initial estimated net operating income ("NOI") yield of 6.8%. Taken together, these 100% leased properties feature a weighted average remaining lease term of 4.4 years. The first quarter activity comprises the following:
<ul>
<li>263,000 square foot industrial building in Cincinnati, Ohio for $23.3 million and an initial estimated NOI yield of 6.7%.</li>
<li>Madison International's 98% joint venture interest in a 297,583 square-foot warehouse facility in Atlanta, Georgia with 100% occupancy for $23.9 million and an initial estimated NOI yield of 6.8%.</li>
<li>The second tranche of the previously announced Cincinnati small bay industrial portfolio consisting of four buildings totaling 240,578 square feet for $17.9 million and representing an estimated NOI yield of 7.0%. &nbsp;</li>
</ul>
Market Portrait Series&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We issued our second Market Portrait with Avison Young highlighting the Memphis industrial market - America's Distribution Center. The Portrait can be found on our corporate website under <a href="https://www.globenewswire.com/Tracker?data=WQ1381YMiTO9gZWqd6tj-ZMNvBYqYE254AygMFMeZN-NmRG6lwAoC9wkc5l3i0enOvFVcIPhVSa3mZAMfWPTGJ-SH_EgQtJUEfOrT84QgHfbXvBabSov5t2KEBwWZyhP5rDZEB_m8nKSLeJgBwdHyw==">Portfolio / Portfolio Map / Memphis</a>.
Known as "America's Distribution Center," Memphis' freight transportation infrastructure connects companies to nearly every major national and international market. Home to the FedEx World SuperHub, Memphis offers local companies an advantage as the cutoff time to drop off packages for next day delivery is later than counterparts in other U.S. cities. The market is served by five Class 1 railroads and is a key market where the eastern railroads CSX and NS can interconnect with western railroads BNSF and UP. In addition, Canadian National offers a key connection from the Gulf Coast to Canada via Memphis. The Memphis region is serviced by six interstate highways, the most significant being I-55 connecting Chicago to New Orleans and I-40 connecting California to North Carolina.
As of December 31, 2024, Memphis was our largest wholly-owned single market position with 63 buildings across approximately 6.4 million square feet.

PLYM

Plymouth REIT Signs Over 2.4M Square Feet in Q1 Leases, Expands Footprint With $65M in New Property Deals, Boosts Occupancy in Key Logistics Hubs

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Biotech

TNXP

Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia At The American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

BRKR

Bruker Launches 1.3 GHz High-Resolution Nuclear Magnetic Resonance System

Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and maintains $65 price target.

Reiteration

DKNG

Needham Reiterates Buy on DraftKings, Maintains $65 Price Target

Bruker Launches Fourier 80 Multinuclear Benchtop FT-NMR Spectrometer To Enable  X-Nucleus Observations And various 2D Experiments

ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA's strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
"ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States," said Adam Grossman, President and Chief Executive Officer of ADMA. "The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The Company's vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution. Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance, but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base."

ADMA

ADMA Highlights US-Based Supply Chain as Key Advantage in Tariff Era

Moderna Will Present Research Across Multiple Infectious Disease Areas, Including COVID-19, Influenza, Respiratory Syncytial Virus, Cytomegalovirus, Norovirus, And mpox, At The European Society Of Clinical Microbiology And Infectious Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

<ul>
<li>Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days.</li>
<li>Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist.</li>
<li>iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026.</li>
</ul>

IBIO

iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preserving And Promoting Muscle Growth

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>, TASE: GILT))), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat Defense was awarded a contract to provide ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed worldwide in support of U.S. Department of Defense (DoD) customers. The contract includes a base program with options to extend up to five years, totaling up to $23 million.
Under the agreement, Gilat Defense will deliver critical program management, field services, and technical support, ensuring operational readiness and continued reliability of these vital communication assets.

GILT

Gilat Wins $23M Deal to Support Satellite Terminals for US Defense Department

<ul>
<li>Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks.</li>
<li>19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks.</li>
<li>20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks.</li>
<li>Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025.</li>
</ul>

RYTM

Rhythm Pharmaceuticals' Phase 3 TRANSCEND Trial Of Setmelanotide For Acquired Hypothalamic Obesity, Met Its Primary Endpoint With Statistically Significant And Highly Clinically Meaningful Reduction In Body Mass Index In Adult And Pediatric Patients Versus Placebo

United Homes Posts 22.9% Decrease In Q1 Net New Orders

Press Releases

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

Comments

AN2 Therapeutics

Notizie

Ultime notizie per AN2 Therapeutics (NASDAQ:ANTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO